Physician profile
Wafa Barkho
NPI 1033349626
$4,230.77
in general payments reported to CMS, 2019-2025
15 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $125 · 2021: $292 · 2022: $322 · 2023: $342 · 2024: $1,341 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $847.73 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $758.26 | 2019-2025 | Repatha, Repatha |
| Lilly USA, LLC | $562.31 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.35 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $346.66 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $302.92 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $231.30 | 2024 | Rexulti |
| Exact Sciences Corporation | $153.97 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $125.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Abbvie INC. | $124.45 | 2025 | |
| Kerecis Limited | $124.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Phadia US INC. | $59.39 | 2022 | |
| Dexcom, INC. | $52.13 | 2024 | Dexcom G6 Transmitter |
| Ascend Therapeutics US, LLC | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wafa Barkho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.